Gain Therapeutics (GANX) Stock Research

Gain Therapeutics

· GANX

Dashboard

Financials

Ratios

Valuation

Statistics

73.321 M

+2.98%

Over a week ago

Gain Therapeutics reports Q2 EPS (11c), consensus (15c)

GANX

Aug 11, 7:17 AM

Closing Bell Movers: AeroVironment jumps after quarterly report

Jun 29, 6:57 PM

Gain Therapeutics receives FDA clearance of GT-02287 IND application

GANX

Jun 29, 4:15 PM

Gain Therapeutics presents data from Phase 1b study of GT-02287

GANX

May 26, 8:36 AM

Gain Therapeutics price target lowered by $2 at Roth Capital, here's why

GANX

May 12, 9:30 AM

Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

GANX

May 11, 7:40 AM

Gain Therapeutics management to meet with Maxim

GANX

Apr 17, 12:17 PM

Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

GANX

Mar 26, 7:22 AM

Gain announces presentations on Phase 1b clinical study of GT-02287

GANX

Mar 18, 8:27 AM

Gain Therapeutics provides regulatory update on GT-02287

GANX

Mar 12, 7:27 AM

Gain Therapeutics provides additional data from Phase 1b study of GT-02287

GANX

Jan 6, 7:21 AM

Gain Therapeutics holds a conference call

GANX

Dec 30, 10:59 AM

Gain Therapeutics price target raised by $4 at Roth Capital, here's why

GANX

Dec 19, 1:34 PM

Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint

GANX

Dec 18, 7:09 AM

Gain Therapeutics presents data on GT-02287

GANX

Nov 20, 7:04 AM

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

GANX

Nov 12, 7:13 AM

Unusually active option classes on open October 22nd

Oct 22, 9:40 AM

Gain Therapeutics price target lowered by $4 at BTIG, here's why

GANX

Oct 16, 7:41 AM

Gain Therapeutics price target raised by $2 at Maxim, here's why

GANX

Oct 7, 9:05 AM

Unusually active option classes on open October 6th

Oct 6, 9:40 AM

Gain Therapeutics presents initial data from Phase 1b study of GT-02287

GANX

Oct 6, 8:32 AM

Charts